BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children’s to Accelerate Development of Genetic Disease Therapeutics Read more
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology Read more
Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis Read more
BioTime and Asterias Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company Read more